Overview
- TickerSANA on Nasdaq1
- IndustryBiological Products, (No Diagnostic Substances)1
- HeadquartersDE1
- Websitesana.com
- Incorporated inDE4
- Business address188 East Blaine Street, Suite 350, Seattle, Wa4
- Filer category, Emerging growth company4
See how the biggest companies compare on our leaderboards
Financials
From the company’s reports to the SEC. Every number links to the filing it came from.
Financial statements
Every line of the income statement as filed: the last 3 fiscal years, latest first.9
| Period ending | 2025-12-31 | 2024-12-31 | 2023-12-31 |
|---|---|---|---|
| Research and development | $132.0M | $215.7M | $261.8M |
| Research and development related success payments and contingent consideration | $29.4M | -$8.9M | -$49.0M |
| General and administrative | $44.3M | $64.0M | $73.3M |
| Impairment of long-lived assets | $44.6M | $1.9M | $7.0M |
| Total operating expenses | $250.3M | $272.7M | $293.1M |
| Loss from operations | -$250.3M | -$272.7M | -$293.1M |
| Interest income, net | $3.8M | $10.5M | $9.9M |
| Other income (expense), net | $2.3M | -$4.5M | -$52.0K |
| Net loss | -$244.2M | -$266.8M | -$283.3M |
| Net loss per common share - basic | -$0.96 | -$1.16 | -$1.46 |
| Net loss per common share - diluted | -$0.96 | -$1.16 | -$1.46 |
| Weighted-average number of common shares - basic | 253.2M shares | 230.9M shares | 194.5M shares |
| Weighted-average number of common shares - diluted | 253.2M shares | 230.9M shares | 194.5M shares |
No quarter-by-quarter statement was filed.
Every line of the balance sheet as filed: the last 4 fiscal years (annual) or 4 quarters (quarterly), latest first.9
| Period ending | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Cash and cash equivalents | $71.9M | $127.6M | $133.5M | |
| Marketable securities | $66.5M | $24.9M | ||
| Restricted cash | $4.2M | $3.8M | ||
| Prepaid expenses and other current assets | $6.1M | $4.5M | ||
| Total current assets | $148.7M | $160.8M | ||
| Property and equipment, net | $26.9M | $77.3M | ||
| Operating lease right-of-use assets | $38.3M | $58.0M | ||
| Intangible asset | $59.2M | $59.2M | ||
| Goodwill | $140.6M | $140.6M | ||
| Other non-current assets | $3.2M | $5.1M | ||
| TOTAL ASSETS | $416.9M | $501.0M | ||
| Accounts payable | $1.7M | $5.2M | ||
| Accrued compensation | $13.2M | $14.4M | ||
| Accrued expenses and other current liabilities | $8.7M | $13.2M | ||
| Operating lease liabilities | $14.9M | $12.5M | ||
| Contingent consideration | $40.2M | $0 | ||
| Total current liabilities | $78.7M | $45.4M | ||
| Operating lease liabilities, net of current portion | $63.9M | $81.7M | ||
| Contingent consideration, net of current portion | $83.5M | $109.0M | ||
| Success payment liabilities | $19.2M | $4.6M | ||
| Other non-current liabilities | $10.6M | $9.9M | ||
| Total liabilities | $256.0M | $250.5M | ||
| Common stock, $0.0001 par value; 750,000 shares authorized; 266,732 and 223,923 shares issued and outstanding as of December 31, 2025 and December 31, 2024, respectively | $27.0K | $22.0K | ||
| Additional paid-in capital | $2.0B | $1.9B | ||
| Accumulated other comprehensive income | $28.0K | $14.0K | ||
| Accumulated deficit | -$1.8B | -$1.6B | ||
| Total stockholders' equity | $160.9M | $250.5M | $287.5M | $499.3M |
| TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY | $416.9M | $501.0M | ||
| Preferred stock, par value | $0.00 | $0.00 | ||
| Preferred stock, shares authorized | 50.0M shares | 50.0M shares | ||
| Preferred stock, shares issued | 0 shares | 0 shares | ||
| Preferred stock, shares outstanding | 0 shares | 0 shares | ||
| Common stock, par value | $0.00 | $0.00 | ||
| Common stock, shares authorized | 750.0M shares | 750.0M shares | ||
| Common stock, shares issued | 266.7M shares | 223.9M shares | ||
| Common stock, shares outstanding | 266.7M shares | 223.9M shares |
| Period ending | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Cash and cash equivalents | $71.9M | $127.6M | $133.5M | |
| Marketable securities | $66.5M | $24.9M | ||
| Restricted cash | $4.2M | $3.8M | ||
| Prepaid expenses and other current assets | $6.1M | $4.5M | ||
| Total current assets | $148.7M | $160.8M | ||
| Property and equipment, net | $26.9M | $77.3M | ||
| Operating lease right-of-use assets | $38.3M | $58.0M | ||
| Intangible asset | $59.2M | $59.2M | ||
| Goodwill | $140.6M | $140.6M | ||
| Other non-current assets | $3.2M | $5.1M | ||
| TOTAL ASSETS | $416.9M | $501.0M | ||
| Accounts payable | $1.7M | $5.2M | ||
| Accrued compensation | $13.2M | $14.4M | ||
| Accrued expenses and other current liabilities | $8.7M | $13.2M | ||
| Operating lease liabilities | $14.9M | $12.5M | ||
| Contingent consideration | $40.2M | $0 | ||
| Total current liabilities | $78.7M | $45.4M | ||
| Operating lease liabilities, net of current portion | $63.9M | $81.7M | ||
| Contingent consideration, net of current portion | $83.5M | $109.0M | ||
| Success payment liabilities | $19.2M | $4.6M | ||
| Other non-current liabilities | $10.6M | $9.9M | ||
| Total liabilities | $256.0M | $250.5M | ||
| Common stock, $0.0001 par value; 750,000 shares authorized; 266,732 and 223,923 shares issued and outstanding as of December 31, 2025 and December 31, 2024, respectively | $27.0K | $22.0K | ||
| Additional paid-in capital | $2.0B | $1.9B | ||
| Accumulated other comprehensive income | $28.0K | $14.0K | ||
| Accumulated deficit | -$1.8B | -$1.6B | ||
| Total stockholders' equity | $160.9M | $250.5M | $287.5M | $499.3M |
| TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY | $416.9M | $501.0M | ||
| Preferred stock, par value | $0.00 | $0.00 | ||
| Preferred stock, shares authorized | 50.0M shares | 50.0M shares | ||
| Preferred stock, shares issued | 0 shares | 0 shares | ||
| Preferred stock, shares outstanding | 0 shares | 0 shares | ||
| Common stock, par value | $0.00 | $0.00 | ||
| Common stock, shares authorized | 750.0M shares | 750.0M shares | ||
| Common stock, shares issued | 266.7M shares | 223.9M shares | ||
| Common stock, shares outstanding | 266.7M shares | 223.9M shares |
Cash flow is reported year to date, not quarter by quarter, so there are no separate quarterly figures.
Every line of the cash flow as filed: the last 3 fiscal years, latest first.9
| Period ending | 2025-12-31 | 2024-12-31 | 2023-12-31 |
|---|---|---|---|
| Net loss | -$244.2M | -$266.8M | -$283.3M |
| Depreciation | $12.8M | $15.5M | $17.5M |
| Stock-based compensation expense | $25.5M | $37.7M | $35.5M |
| Change in the estimated fair value of contingent consideration | $14.8M | -$638.0K | -$40.8M |
| Change in the estimated fair value of success payment liabilities | $14.7M | -$8.2M | -$8.2M |
| Non-cash expense for operating lease right-of-use assets | $9.2M | $9.7M | $13.3M |
| Impairment of long-lived assets | $44.6M | $1.9M | $7.0M |
| Other non-cash items, net | -$11.0M | -$11.1M | -$13.3M |
| Prepaid expenses and other assets | $1.2M | -$3.5M | $8.1M |
| Operating lease right-of-use assets and liabilities | -$3.0M | $9.3M | $11.0M |
| Accounts payable | -$3.5M | $1.4M | $1.0M |
| Accrued expenses and other liabilities | -$4.7M | -$8.4M | -$1.5M |
| Net cash used in operating activities | -$143.8M | -$223.2M | -$253.6M |
| Purchases of marketable securities | -$87.3M | -$226.1M | -$157.7M |
| Proceeds from maturities of marketable securities | $46.6M | $276.9M | $349.8M |
| Purchases of property and equipment | -$938.0K | -$33.4M | -$20.0M |
| Proceeds from disposal of assets | $1.4M | $0 | $0 |
| Net cash provided by (used in) investing activities | -$40.2M | $17.5M | $172.0M |
| Proceeds from employee stock purchase plan and exercise of stock options | $2.7M | $11.0M | $4.6M |
| Proceeds related to common stock financings, net | $126.4M | $181.0M | $27.0M |
| Proceeds (principal payments), net for tenant improvement loan | -$347.0K | $7.7M | $0 |
| Net cash provided by financing activities | $128.7M | $199.7M | $31.6M |
| Net decrease in cash, cash equivalents, and restricted cash | -$55.3M | -$6.0M | -$49.9M |
| Operating lease right-of-use assets obtained in exchange for lease obligations | $0 | $0 | $9.0M |
| Purchases of property and equipment included in accounts payable and accrued liabilities | $0 | $0 | $9.5M |
| Cash received for tenant improvement allowances | $891.0K | $7.5M | $12.5M |
| Derecognition of operating lease right-of-use assets for lease termination and modification | -$2.7M | -$7.3M | -$14.2M |
No quarter-by-quarter statement was filed.
Leadership
Who has led Sana Biotechnology, and when. Pick a name to see everywhere that person has worked.
Chief executive
President
Chief financial officer
2025
- Chief executive officerSteve Harr Feb 3, 2021 to now12
- PresidentSteve Harr Feb 3, 2021 to now12
- Chief financial officerBrian Piper Feb 18, 2026 to now13
- Chief financial officerNathan Hardy Feb 3, 2021 to Mar 8, 202414
Board members and other officers (21)
- EVP, Chief Scientific OfficerDhavalkumar Dhirajlal Patel Mar 27, 2026 to now15
- OfficerSusan D. Wyrick Oct 15, 2024 to now16
- EVP & President, R&DDouglas E. Williams Apr 11, 2023 to Mar 8, 202417
- SVP, Chief Business OfficerChristian Hordo Feb 3, 2021 to Mar 8, 202418
- OfficerJames J. Macdonald Feb 3, 2021 to Feb 10, 202119
- Head of SanaXRichard Mulligan Feb 3, 2021 to Mar 3, 202320
- OfficerSunil Agarwal Feb 3, 2021 to Mar 8, 202221
- Board memberRobert L. Rosiello Jun 9, 2025 to now22
- Board memberAlise Reicin Feb 3, 2021 to now23
- Board memberDouglas G. Cole Feb 3, 2021 to Jul 15, 202424
- Board memberHans Bishop Feb 3, 2021 to now25
- Board memberJoshua H. Bilenker Feb 3, 2021 to now26
- Board memberMaltzahn Geoffrey Von Feb 3, 2021 to Feb 18, 202127
- Board memberMary Agnes Wilderotter Feb 3, 2021 to now28
- Board memberMichelle Seitz Feb 3, 2021 to now29
- Board memberPatrick Y. Yang Feb 3, 2021 to now30
- Board memberRichard Mulligan Feb 3, 2021 to now20
- Board memberRobert Nelsen Feb 3, 2021 to now31
- Board memberSteve Harr Feb 3, 2021 to now12
- General counselJames J. Macdonald Feb 23, 2022 to Jun 15, 202232
- General counselBernard J. Cassidy Sep 16, 2022 to now33
Timeline
- Feb 3, 2021New chief executive Steve Harr becomes CEO12
Filings
300 filings to the SEC since October 2021: 5 annual reports, 15 quarterly reports, 59 major events, 140 insider forms, 28 large holders, 53 other. The latest 20:
- Oct 6, 20264 PRIMARY DOCUMENT EDGAR
- Sep 8, 20268-K EDGAR
- Aug 27, 20264 PRIMARY DOCUMENT EDGAR
- Aug 14, 2026SCHEDULE 13G/A EDGAR
- Aug 10, 202610-Q EDGAR
- Aug 10, 20268-K EDGAR
- Jul 7, 20264 PRIMARY DOCUMENT EDGAR
- Jun 5, 20264 PRIMARY DOCUMENT EDGAR
- Jun 5, 20264 PRIMARY DOCUMENT EDGAR
- Jun 5, 20264 PRIMARY DOCUMENT EDGAR
- Jun 5, 20264 PRIMARY DOCUMENT EDGAR
- Jun 5, 20264 PRIMARY DOCUMENT EDGAR
- Jun 5, 20264 PRIMARY DOCUMENT EDGAR
- Jun 5, 20264 PRIMARY DOCUMENT EDGAR
- Jun 5, 20264 PRIMARY DOCUMENT EDGAR
- Jun 5, 20268-K EDGAR
- May 21, 2026SCHEDULE 13G EDGAR
- May 15, 20268-K EDGAR
- May 11, 2026S-8 EDGAR
- May 11, 202610-Q EDGAR
The 300 filings since October 2021 can be filtered by form type and year here when JavaScript is on.
Every filing from the last three years, summarized. The full record is on SEC EDGAR.
Insider trades and holders
Large holders
Investors who own more than 5% must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively. 28 such filings since October 2021, the latest 10:
- Aug 14, 2026SCHEDULE 13G/A
- May 21, 2026SCHEDULE 13G
- Jan 21, 2026SCHEDULE 13G
- Nov 14, 2025SCHEDULE 13G/A
- Jan 31, 2025SCHEDULE 13G/A
- Nov 14, 2024SC 13G/A
- Nov 14, 2024SC 13G/A
- Nov 12, 2024SC 13G/A
- Nov 12, 2024SC 13G/A
- Nov 8, 2024SC 13G
From Forms 4 and Schedules 13D and 13G filed with the SEC.
Held by these funds
The largest holders among investment managers' 13F reports for the quarter ending Jun 30, 2026, the top 25 of 100. Change is in shares since the quarter before.
| Fund | Shares | Value | Share of the fund | Change |
|---|---|---|---|---|
| Fmr LLC | 37,429,515 | $130.6M | 0.0% | −769 |
| Flagship Pioneering, LLC | 25,001,856 | $87.3M | 5.7% | No change |
| Ra Capital Management, L.P. | 18,750,000 | $65.4M | 0.6% | New |
| BlackRock, Inc. | 16,675,173 | $58.2M | 0.0% | +2,434,998 |
| State Street Corp | 11,203,134 | $39.1M | 0.0% | +665,048 |
| Canada Pension Plan Investment Board | 10,218,400 | $35.7M | 0.0% | −3,500 |
| Vanguard Capital Management LLC | 8,375,421 | $29.2M | 0.0% | +940,697 |
| Bank Of America Corp /de/ | 5,748,454 | $20.1M | 0.0% | +2,801,593 |
| Geode Capital Management, LLC | 4,677,959 | $16.3M | 0.0% | +495,986 |
| Marex Group Ltd | 3,989,100 | $13.9M | 0.1% | −10,000 |
| Marshall Wace, Llp | 2,931,436 | $10.2M | 0.0% | +2,266,979 |
| Alphabet Inc. | 2,812,500 | $9.8M | 0.0% | No change |
| Goldman Sachs Group Inc | 2,367,935 | $8.3M | 0.0% | −813,180 |
| Integral Health Asset Management, LLC | 2,000,000 | $7.0M | 0.3% | −1,200,000 |
| Toronto Dominion Bank | 1,972,381 | $6.9M | 0.0% | New |
| Vanguard Portfolio Management LLC | 1,881,689 | $6.6M | 0.0% | +174,168 |
| Jacobs Levy Equity Management, Inc | 1,868,718 | $6.5M | 0.0% | New |
| Northern Trust Corp | 1,604,084 | $5.6M | 0.0% | +125,233 |
| Charles Schwab Investment Management Inc | 1,379,181 | $4.8M | 0.0% | +13,033 |
| Woodline Partners LP | 1,317,932 | $4.6M | 0.0% | No change |
| Vanguard Fiduciary Trust Co | 1,237,437 | $4.3M | 0.0% | +173,788 |
| Renaissance Technologies LLC | 1,231,100 | $4.3M | 0.0% | −220,100 |
| Morgan Stanley | 1,139,782 | $4.0M | 0.0% | −320,233 |
| UBS Group AG | 1,061,441 | $3.7M | 0.0% | −293,848 |
| Aqr Capital Management LLC | 963,147 | $3.4M | 0.0% | −161,132 |
13F reports cover disclosed long positions in U.S. stocks only.
Links
- Websitesana.com1
- WikidataQ106301980
- SEC EDGARCIK 1770121
Sources
The numbers on this page point here. Each one links to the record it came from.
- 1WikidataSana Biotechnology on Wikidata
- 2
- 3Company websiteSana Biotechnology logo
- 4
- 5
- 6
- 7
- 8
- 9
- 10
- 11
- 12SEC EDGARSteve Harr, Chief executive officer
- 13SEC EDGARBrian Piper, Chief financial officer
- 14
- 15
- 16SEC EDGARSusan D. Wyrick, Officer
- 17
- 18
- 19SEC EDGARJames J. Macdonald, Officer
- 20SEC EDGARRichard Mulligan, Head of SanaX
- 21SEC EDGARSunil Agarwal, Officer
- 22SEC EDGARRobert L. Rosiello, Board member
- 23SEC EDGARAlise Reicin, Board member
- 24SEC EDGARDouglas G. Cole, Board member
- 25SEC EDGARHans Bishop, Board member
- 26SEC EDGARJoshua H. Bilenker, Board member
- 27SEC EDGARMaltzahn Geoffrey Von, Board member
- 28SEC EDGARMary Agnes Wilderotter, Board member
- 29SEC EDGARMichelle Seitz, Board member
- 30SEC EDGARPatrick Y. Yang, Board member
- 31SEC EDGARRobert Nelsen, Board member
- 32SEC EDGARJames J. Macdonald, General counsel
- 33SEC EDGARBernard J. Cassidy, General counsel